JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peter, M.
Right arrow Articles by Burckhardt, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peter, M.
Right arrow Articles by Burckhardt, D.

The Journal of Thoracic and Cardiovascular Surgery, Vol 106, 599-608, Copyright © 1993 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association


ARTICLES

The Omnicarbon tilting-disc heart valve prosthesis. A clinical and Doppler echocardiographic follow-up

M Peter, P Weiss, HR Jenzer, A Hoffmann, P Dubach, J Roth, W Bertschmann, P Stulz, E Gradel and D Burckhardt
Division of Cardiology and Cardiothoracic Surgery, University Hospital, Basel, Switzerland.

From 1986 to 1990, 172 patients with a median age of 60.5 years (range 20 to 79 years) received 187 Omnicarbon valves (109 aortic valve replacements, 48 mitral valve replacements, and 15 double valve replacements). Patients were followed-up for a median observation period of 2.5 years (range 4 months to 5.2 years) by clinical and Doppler echocardiographic examination. Follow-up was complete in 98%. Operative mortality (death within 30 days) was 1.7%, and linearized late mortality was 2.6% per patient-year, corresponding to an actuarial survival rate for operative survivors of 89% after 4 years. The overall 4-year postoperative survival was 87% (93% for aortic valve replacement, 77% for mitral valve replacement). Compared with age- and sex-adjusted Swiss death rates, there was an excess mortality of 5% after 4 years. Percentages for freedom from valve-related complications at 4 years are as follows: thromboembolism, 98% (aortic valve replacement, 98%, and mitral valve replacement, 96%); anticoagulant- related hemorrhage, 95%; valve endocarditis, 96%; reoperation, 96%; and permanent valve-related impairment, 99%. The overall 4-year event-free survival was 76% (80% for aortic valve replacement and 69% for mitral valve replacement). New York Heart Association class improved in 88% of the patients by 1 to 3 grades, and only 3% remained in class III after operation. For the most commonly used aortic valve (23 mm), Doppler echocardiography revealed a peak pressure gradient of 29 +/- 10 mm Hg, a fractional shortening/peak pressure gradient ratio of 1.34 +/- 0.61, and a performance index of 0.35 +/- 0.08. In the most commonly used mitral valve (27 mm), the mean pressure gradient was 4.0 +/- 2.1 mm Hg. We conclude that excellent clinical and hemodynamic results can be obtained with the Omnicarbon prosthesis, in both the aortic and mitral positions.


This article has been cited by other articles:


Home page
Card Surg AdultHome page
T. Gudbjartsson, T. Absi, and S. Aranki
Mitral Valve Replacement
Card. Surg. Adult, January 1, 2008; 3(2008): 1031 - 1068.
[Full Text]


Home page
J Am Coll CardiolHome page
R. Vink, R. A. Kraaijenhagen, B. A. Hutten, R. B. A. van den Brink, B. A. de Mol, H. R. Buller, and M. Levi
The optimal intensity of vitamin k antagonists in patients with mechanical heart valves: A meta-analysis
J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2042 - 2048.
[Abstract] [Full Text] [PDF]


Home page
Card Surg AdultHome page
T. Gudbjartsson, S. Aranki, and L. H. Cohn
Mechanical/Bioprosthetic Mitral Valve Replacement
Card. Surg. Adult, January 1, 2003; 2(2003): 951 - 986.
[Full Text]


Home page
Eur Heart J SupplHome page
C. Huth, A. Friedl, A. Rost, and for the GELIA Study Investigator Group
Intensity of oral anticoagulation after implantation of St. Jude Medical aortic prosthesis: analysis of the GELIA Database (GELIA 4)
Eur. Heart J. Suppl., December 1, 2001; 3(suppl_Q): Q33 - Q38.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
O. Bech-Hanssen, K. Caidahl, I. Wallentin, P. Ask, and B. Wranne
Assessment of effective orifice area of prosthetic aortic valves with Doppler echocardiography: An in vivo and in vitro study
J. Thorac. Cardiovasc. Surg., August 1, 2001; 122(2): 287 - 295.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
S. Torregrosa, J. Gomez-Plana, F. J. Valera, J. Caffarena, J. M. Maronas, F. Garcia-Sanchez, J. Peris, R. Frias, and J. M. Caffarena
Long-term clinical experience with the omnicarbon prosthetic valve
Ann. Thorac. Surg., September 1, 1999; 68(3): 881 - 886.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1993 by The American Association for Thoracic Surgery.